Loading...
•
Dec 31, 2019
Corvus Pharmaceuticals Q4 2019 Earnings Report
Corvus Pharmaceuticals reported financial results for Q4 2019 and provided a business update.
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $11.0 million for the fourth quarter of 2019, with research and development expenses totaling $8.9 million. The company's cash, cash equivalents, and marketable securities amounted to $78.0 million as of December 31, 2019.
Advanced pipeline with three candidates in clinical trials.
Presented updated data for clinical programs at major medical meetings.
Academic collaborators are publishing data from studies in peer-reviewed journals.
Reported responses in patients with advanced refractory renal cell cancer.
Corvus Pharmaceuticals
Corvus Pharmaceuticals
Forward Guidance
Corvus expects full year 2020 net cash used in operating activities to be between $39 million and $42 million.